Bioactivity:

SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.

CAS nr:

908115-27-5

Purity:

98%

Molecular Weight:

521,53

SMILES:

CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1

Formula:

C25H30F3N5O4

Pathway:

Tyrosine Kinase/Adaptors,Metabolism,Cytoskeletal Signaling,Angiogenesis,JAK/STAT signaling

Target:

HER,HSP,HSP,HER,HER